Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus salmeterol + fluticasone for prevention of COPD exacerbations over 52 weeks
2012-004966-16Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol, glycopyrronium, salmeterol and fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Rate of COPD exacerbations. Started Jan 2013; status: completed.
02
Drugs
indacaterolglycopyrroniumsalmeterolfluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-004966-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004966-16.